On Friday, August 7th, the FDA announced the approval of Evrysdi (Risdiplam), the first oral treatment for all types of SMA. BioNews frequently launches surveys to gauge the thoughts of community members. Your perspective may help better inform and improve how the medical industry treats people with SMA. Should this survey yield valuable insights, the results will be shared with the SMA community. This survey will take 2-3 minutes to complete. Your insights are appreciated.
I realize that the research costs a lot of money but the price of Evrysdi is going to make it really difficult for many to afford this breakthrough treatment.
I stay in South Africa and except that it is not available here yet I would never be able to afford it.
Currently in South Africa our medical aid companies see SMA as ‘another genetic disorder’ and does not classify it under muscular dystrophy as the US and Britain does. This means it does not get funded under prescribed minimum benefits but rather comes off from my medical savings plan. Any treatment like physio or assistive devices like wheelchairs also comes off from the savings plan. It’s quite ridiculous actually.
I personally don’t think, and I sincerely hope I’m wrong, that our medical aid companies will cover a lot of the cost leaving many like myself and my sister who both have SMA3 out in the cold.
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.